Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. | Zendy

E. Clarke Haley | Zendy; Thomas Brott | Zendy; G L Sheppard | Zendy; William G. Barsan | Zendy; J. P. Broderick | Zendy; John R. Marler | Zendy; Gail L. Kongable | Zendy; Judith Spilker | Zendy; Sandra Massey | Zendy; Carolyn Apperson-Hansen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.

Author(s) -

E. Clarke Haley,

Thomas Brott,

G L Sheppard,

William G. Barsan,

J. P. Broderick,

John R. Marler,

Gail L. Kongable,

Judith Spilker,

Sandra Massey,

Carolyn Apperson-Hansen

Publication year - 1993

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.24.7.1000

Subject(s) - medicine , plasminogen activator , placebo , tissue plasminogen activator , recombinant dna , t plasminogen activator , randomized controlled trial , recombinant tissue plasminogen activator , stroke (engine) , clinical endpoint , surgery , anesthesia , ischemia , ischemic stroke , pathology , modified rankin scale , mechanical engineering , biochemistry , chemistry , alternative medicine , engineering , gene

Early thrombolytic therapy with recombinant tissue-type plasminogen activator is a theoretically attractive approach to the treatment of acute focal cerebral ischemia. In preparation for a larger multicenter trial, three centers piloted a protocol for a randomized, double-blind, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator begun within 3 hours of the onset of symptoms of acute stroke to test its feasibility and to explore trends.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research